Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcin.2022.06.035 | DOI Listing |
J Cardiovasc Dev Dis
December 2024
2nd Cardiology Department, Interbalkan Medical Center, 55535 Thessaloniki, Greece.
Background: Mitral regurgitation (MR) is a common valvular disorder linked to high morbidity and mortality. For patients unsuitable for surgery, transcatheter mitral edge-to-edge repair (TEER) with the MitraClip G4 system offers an alternative. This study aims to evaluate procedural, echocardiographic, functional, and quality of life (QoL) outcomes in patients who underwent TEER with the MitraClip G4 system, along with possible predictors of New York Heart Association (NYHA) class I at 30 days and at 1 year.
View Article and Find Full Text PDFJ Am Coll Cardiol
January 2025
University Medical Center Mainz, Mainz, Germany. Electronic address:
J Am Coll Cardiol
January 2025
Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
Cardiovasc Interv Ther
January 2025
Heart Valve Center, IRCCS San Raffaele, Milan, Italy.
Background: Treatment of residual mitral regurgitation (MR) with different percutaneous devices after transcatheter edge-to-edge repair (TEER) has been reported as an alternative option to reclipping or surgery. This review aims at describing the different transcatheter strategies available and their results when managing residual MR after TEER.
Methods: A literature search was undertaken across Pubmed, ScienceDirect, SciELO, DOAJ, and Cochrane library databases, to identify article reporting patients with post-TEER residual MR managed by a transcatheter approach that did not involve only the implantation of new clips.
Circ Cardiovasc Interv
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!